Complete response to short‐term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases

Abstract

We report a 60-year-old male patient who developed extrahepatic metastases in bone, peritoneum, and lymph nodes (confirmed by computed tomography and positron emission tomography-computed tomography) after hepatectomy for hepatocellular carcinoma. He was treated with sorafenib (800 mg/day) but developed grade 3 hand-foot syndrome. He continued to be treated with sorafenib but at a lower dose (400 mg/week). The response to sorafenib therapy was graded as complete response at 6 months by the Response Evaluation Criteria in Solid Tumors. Sorafenib was continued for 8 months and the patient remained in complete response for 11 months. Further reporting of similar cases should help design treatment strategies and evaluate predictors of the response to sorafenib therapy.

Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report

“…The response to combination therapy was graded as CR achieved at 6 months. Sorafenib was continued for 8 months and the patient remained in CR for 11 months 12 .…”

“…Surprisingly, in this case, the dose of sorafenib was very low. Nakano et al 12 proposed that either sorafenib or denosumab produced an effective response for bone metastases, and a late response to IFN was possible. In any event, these two cases did not use monotherapy, but used combination therapy instead.…”

Comment on “combination treatment including targeted therapy for advanced hepatocellular carcinoma”

“…In addition, targeted therapy also prolonged survival time in the advanced cancer patients with metastasis. Nakano et al reported a case that a HCC patient with bone, lymph node and peritoneum metastases obtained complete response to short-term sorafenib treatment alone (15). Although these individual cases are infrequent, these hint us to a more personalized approach to medicine and of genomic investigations of tumors should be explored.…”